{
    "nctId": "NCT00813956",
    "briefTitle": "A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer",
    "officialTitle": "N/A",
    "overallStatus": "COMPLETED",
    "conditions": "Triple Negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 80,
    "primaryOutcomeMeasure": "pathologic complete response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* invasive breast cancer\n* stage I-IIIA disease\n* ER, PR, Her2/neu-negative status\n* no prior treatment for breast cancer\n* age 18 years of greater\n* normal renal, liver function\n* normal hematologic status\n* ECOG Performance status 0, 1\n* Evaluation by a surgeon to determine breast conservation eligibility\n* Women of childbearing potential must have a documented negative pregnancy test within 2 months of study trial entry and agree to birth control during the duration of the trial therapy\n* Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Metastatic breast cancer\n* Inoperable breast cancer, including Stage IIIB and IIIC\n* Tumor size less than 1 centimeter\n* Prior surgery, systemic therapy, or radiotherapy for the current cancer\n* Hormone receptor-positive breast cancer\n* Her2/neu-positive breast cancer\n* Any concurrent condition which in the investigator's opinion makes it inappropriate for the patient to participate in the trial or which would jeopardize compliance with the protocol\n* Pregnant or nursing women\n* Receipt of any investigational agents within 30 days prior to commencing study treatment",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}